Geode Capital Management LLC Buys 127,708 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Geode Capital Management LLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 2.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,837,985 shares of the biotechnology company’s stock after buying an additional 127,708 shares during the period. Geode Capital Management LLC owned approximately 2.34% of BioCryst Pharmaceuticals worth $36,776,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Counterweight Ventures LLC boosted its holdings in BioCryst Pharmaceuticals by 591.7% during the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock valued at $710,000 after acquiring an additional 79,884 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock worth $2,274,000 after purchasing an additional 86,571 shares during the last quarter. XTX Topco Ltd boosted its stake in BioCryst Pharmaceuticals by 299.0% during the 2nd quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after purchasing an additional 117,607 shares during the period. Seven Eight Capital LP boosted its position in shares of BioCryst Pharmaceuticals by 1,407.1% in the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after acquiring an additional 158,358 shares during the period. Finally, Rice Hall James & Associates LLC boosted its holdings in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 1.4 %

BCRX stock opened at $7.67 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The business’s 50-day moving average price is $7.63 and its two-hundred day moving average price is $7.45. The firm has a market cap of $1.59 billion, a PE ratio of -12.57 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The company’s revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.19) earnings per share. On average, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Analyst Ratings Changes

BCRX has been the topic of a number of research reports. Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.